Standardization of PD-L1 immunohistochemistry
Modern Pathology 2022 35:294–295. DOI: 10.1038/s41379-021-00917-4
BCS is proud to announce the launch of the Consortium for Analytic Standardization in Immunohistochemistry (CASI), funded with a grant from the National Cancer Institute. Its mission is to improve immunohistochemistry (IHC) test accuracy and reproducibility by integrating analytic standards into routine practice. To accomplish this mission, the consortium has two mandates: (a) experimentally determine analytic sensitivity thresholds (lower and upper limits of detection) for selected IHC assays, and (b) to inform IHC stakeholders what analytic standards are, why they are important, and how and for what purpose they are used. As such, CASI needs the cooperation from many IHC laboratories who are willing to run one IHCalibrator slide per assay to generate the needed data.
Because IHControls® and IHCalibrators® are leading-edge technology, they have been the subject of extensive research, much of which is supported by the National Cancer Institute. Many of the findings were published in prestigious journals in the fields of laboratory medicine histology and histopathology.
Modern Pathology 2022 35:294–295. DOI: 10.1038/s41379-021-00917-4
Modern Pathology 2021 35:326–332. DOI: 10.1038/s41379-021-00884-w
Archives of Pathology & Laboratory Medicine, DOI: 10.5858/arpa.2017-0330-OA
Journal of Histochemistry & Cytochemistry, DOI: 10.1369/00221554188240920
Journal of Histochemistry & Cytochemistry, DOI: 10.1369/0022155417694869
Journal of Histochemistry & Cytochemistry, DOI: 10.1369/0022155417714208
Clinical Chemistry, DOI: 10.1093/clinchem/hvab008
Applied Immunohistochemistry & Molecular Morphology, DOI: 10.1097/PAI.0000000000000750
Appl. Immunohistochem. Mol. Morphol., 2016 24(10):688-694. DOI: 10.1097/PAI.0000000000000260
J. Histochem. Cytochem, 2015 63:681-690. DOI: 10.1369/0022155415588109
Biotechnic & Histochem. 84(5):207-215. DOI: 10.3109/10520290903039078
Appl Immunohistochem Mol Morphol . 2009 May;17(3):239-46. DOI: 10.1097/PAI.0b013e3181904379 PMID: 19077907; PMCID: PMC2672113
Blood 2008 Jan 1;111(1):302-8. doi: 10.1182/blood-2007-05-090654. Epub 2007 Sep 18. PMID: 17878398 PMCID: PMC2200814
Arch Pathol Lab Med . 2008 Feb;132(2):211-6. doi: 10.5858/2008-132-211-NHPTRU. PMID: 18251579
J Immunol Methods . 2006 Dec 20;317(1-2):80-9. doi: 10.1016/j.jim.2006.09.009. PMID: 17056057 PMCID: PMC1847343
Am J Clin Pathol . 2006 Jan;125(1):82-90. PMID: 16482995
Am J Clin Pathol . 2006 Jan;125(1):91-8. PMID: 16482996
Anal Biochem 2004 Mar 1;326(1):55-68. doi: 10.1016/j.ab.2003.11.008. PMID: 14769336
Am J Clin Pathol 2004 Feb;121(2):190-9. doi: 10.1309/BRN7-CTX1-E84N-WWPL. PMID: 14983931
Journal of Histotechnology Volume 26, 2003 - Issue 2. https://doi.org/10.1179/his.2003.26.2.117
J Histochem Cytochem . 2002 Nov;50(11):1425-34. doi: 10.1177/002215540205001101. PMID: 12417607
December 08, 2020
March 04, 2021
October 7, 2022
October 7, 2022
October 6, 2022
October 6, 2022
October 6, 2022
October 6, 2022
October 6, 2022
October 6, 2022
April 7, 2022
March 8, 2022
AACR 2021
SABCS 2020
Introduction and clinical validation of metrology standards for immunohistochemistry (IHC); new tool for standardization of estrogen receptor (ER) IHC assay in breast cancer
Analysis of PD-L1 IHC assays using NIST SRM 1934-traceable reference materials: A new paradigm for development of predictive IHC biomarkers
As evidenced by the collaborations in our publications, abstracts, posters, and collaborative studies, we value external collaborations that are ultimately aimed at delivering better patient care. If you see an opportunity to improve biomedical testing where we might be able to help, please contact us.
We have a high interest in collaborations leading to IHC assay standardization. Now that IHC laboratories can measure analytic sensitivity (lower limit of detection) by using IHCalibrators®, there is an important pending question for many, possibly most, IHC tests: To identify the analytic sensitivity that best correlates with diagnostically accurate test results. In other words, for IHC tests, what lower limit of detection yields the best fit-for-purpose result? We are looking for surgical pathology collaborators interested in developing data-driven guidelines.